Immunethep - Anti-Bacterial Immunotherapy

We discovered that a single molecule (extracellular protein) which is excreted by the pathogenic bacteria is able to completely shut down the host immune system, letting the bacteria thrive and causing severe infections. Thus, by neutralizing this molecule we can induce protection.

By addressing an extracellular virulence factor that is highly conserved in the different bacteria, our anti-bacterial immunotherapy elicits protective antibodies against all the serotypes of the referred bacterial pathogens. This way, it will also prevent the emergence of strains which are not addressed by current vaccines that only address structural epitopes.

The first product, PNV1 - Paragon Novel Vaccine, is a preventive strategy that will confer a robust protection against the main life threatening bacterial infections.

Immunethep’s PNV1 will be the first vaccine able to prevent multi-bacterial infections from all its serotypes from the womb until elderhood.

“There are high proportions of antibiotic resistance in bacteria that cause common infections (e.g. urinary tract infections, pneumonia, bloodstream infections) in all regions of the world.” [..] “.. antibiotic resistance is no longer a prediction for the future; it is happening right now, across the world, and is putting at risk the ability to treat common infections in the community and hospitals.”

“Resistance to one of the most widely used antibacterial drugs for the oral treatment of urinary tract infections caused by E. coli – fluoroquinolones – is very widespread.” [..] “Resistance to first-line drugs to treat infections caused by Staphlylococcus aureus – a common cause of severe infections acquired both in health-care facilities and in the community – is also widespread.” [..] “Resistance to the treatment of last resort for life-threatening infections caused by common intestinal bacteria” [..] “has spread to all regions of the world.”

“Patients with infections caused by drug-resistant bacteria are generally at increased risk of worse clinical outcomes and death, and consume more health-care resources than patients infected with the same bacteria that are not resistant.”

“Antimicrobial resistance kills: As an example, people with MRSA (methicillin-resistant Staphylococcus aureus, another common source of severe infections in the community and in hospitals) are estimated to be 64% more likely to die than people with a non-resistant form of the infection.”

“Antimicrobial resistance hampers the control of infectious diseases: Antimicrobial resistance reduces the effectiveness of treatment; thus patients remain infectious for a longer time, increasing the risk of spreading resistant microorganisms to others.”